News: CRISPR screening unveils ATXN3 as a new cancer treatment target | Genetic Engineering Publications - GEG Tech top picks | Scoop.it
Utilizing CRISPR screening, the deubiquitinase ATXN3 has been identified as a key regulator of PD-L1 transcription in tumor cells, a critical factor in tumor immune evasion.